Biography—David Menter

Biography—David Menter CancerMetastasisRev(2017)36:191 DOI 10.1007/s10555-017-9676-y Springer Science+Business Media, LLC 2017 Waun Ki Hong, M.D., to develop the Lung Cancer Biomarkers Core Program in the Department of Thoracic/Head and Neck Medical Oncology. Several years later, the trio would work to- gether once more to provide the infrastructure for the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trials. He was first to study the role of neurotrophins in brain cancer metastasis and to im- plement the use of CreERT conditionally targeted mice to exam- ine the role of selenium and selenoproteins in prostate cancer. More recently, Dr. Menter worked with Drs. Raymond DuBois, M.D., Ph.D., and Ernest Hawk, M.D., M.P.H, where he gained extensive experience with NSAIDs COXIBs and aspirin and colorectal cancer biology. He also developed experience with development of nanoparticle delivery vehicles for the treatment of GI cancers and the development of next-generation animal David Menter, Ph.D., is an assistant professor of Gastrointestinal models of GI cancers. He helped found ACF-Pharmaceuticals Medical Oncology at the MD Anderson Cancer Center. He LLP and serves on its executive board as a member and as chief trained with Kenneth Honn, Ph.D., and Lawrence Marnett, scientific officer. He is involved in establishing the Center Ph.D., in the study of prostaglandins in the molecular and cel- for Professional Development and Entrepreneurship as part lular biology of cancer. He published many of the early seminal of an MD Anderson program to support the innovation and papers on the role of platelets in cancer metastasis. His experi- commercialization of new technology by helping provide ence with prostaglandins and other bioactive lipids extends to a curricular offerings, collaborative networks, and profes- chapter in Prostaglandins and Cancer: The First International sional guidance. Conference, published in 1981. Drs. Honn and Menter recently Dr. Menter serves as scientific director of the Colorectal contributed to the second edition of Platelets in Thrombotic and Cancer-Moon Shot. He and Scott Kopetz, M.D., Ph.D., are Non-Thrombotic Disorders, edited by Paolo Gresele, Neal investigating the importance of colorectal cancer consensus molecular subtypes (CMS) as part of their Integromics pro- Kleiman, José Lopez, and Clive Page. Dr. Menter is an expert in the study of prostaglandins; cyclooxygenase-1 and -2; pros- gram, which utilizes and integrates next-generation sequenc- taglandin E -mediated and CSN6 signal transduction; and in- ing and other molecular data to understand the four different flammation and carcinogenesis. CMS subtypes of colorectal cancer. He also is developing Dr. Menter was awarded a National Institutes of Health post- novel mouse models to better understand the role of platelets doctoral fellowship in Human Genetics. He was then promoted in cancer and metastasis in collaboration with Anil Sood, to assistant professor and worked with Scott Lippman, M.D., to M.D., who discovered the systemic tumor-IL6: liver- establish the Department of Clinical Cancer Prevention in the thrombopoeitin: bone marrow platelet overproduction loop Division of Cancer Prevention, and then with Dr. Lippman and that drives Trousseau’ssyndrome in cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer and Metastasis Reviews Springer Journals

Biography—David Menter

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/biography-david-menter-xXQewubo07
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Biomedicine; Cancer Research; Oncology; Biomedicine, general
ISSN
0167-7659
eISSN
1573-7233
D.O.I.
10.1007/s10555-017-9676-y
Publisher site
See Article on Publisher Site

Abstract

CancerMetastasisRev(2017)36:191 DOI 10.1007/s10555-017-9676-y Springer Science+Business Media, LLC 2017 Waun Ki Hong, M.D., to develop the Lung Cancer Biomarkers Core Program in the Department of Thoracic/Head and Neck Medical Oncology. Several years later, the trio would work to- gether once more to provide the infrastructure for the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trials. He was first to study the role of neurotrophins in brain cancer metastasis and to im- plement the use of CreERT conditionally targeted mice to exam- ine the role of selenium and selenoproteins in prostate cancer. More recently, Dr. Menter worked with Drs. Raymond DuBois, M.D., Ph.D., and Ernest Hawk, M.D., M.P.H, where he gained extensive experience with NSAIDs COXIBs and aspirin and colorectal cancer biology. He also developed experience with development of nanoparticle delivery vehicles for the treatment of GI cancers and the development of next-generation animal David Menter, Ph.D., is an assistant professor of Gastrointestinal models of GI cancers. He helped found ACF-Pharmaceuticals Medical Oncology at the MD Anderson Cancer Center. He LLP and serves on its executive board as a member and as chief trained with Kenneth Honn, Ph.D., and Lawrence Marnett, scientific officer. He is involved in establishing the Center Ph.D., in the study of prostaglandins in the molecular and cel- for Professional Development and Entrepreneurship as part lular biology of cancer. He published many of the early seminal of an MD Anderson program to support the innovation and papers on the role of platelets in cancer metastasis. His experi- commercialization of new technology by helping provide ence with prostaglandins and other bioactive lipids extends to a curricular offerings, collaborative networks, and profes- chapter in Prostaglandins and Cancer: The First International sional guidance. Conference, published in 1981. Drs. Honn and Menter recently Dr. Menter serves as scientific director of the Colorectal contributed to the second edition of Platelets in Thrombotic and Cancer-Moon Shot. He and Scott Kopetz, M.D., Ph.D., are Non-Thrombotic Disorders, edited by Paolo Gresele, Neal investigating the importance of colorectal cancer consensus molecular subtypes (CMS) as part of their Integromics pro- Kleiman, José Lopez, and Clive Page. Dr. Menter is an expert in the study of prostaglandins; cyclooxygenase-1 and -2; pros- gram, which utilizes and integrates next-generation sequenc- taglandin E -mediated and CSN6 signal transduction; and in- ing and other molecular data to understand the four different flammation and carcinogenesis. CMS subtypes of colorectal cancer. He also is developing Dr. Menter was awarded a National Institutes of Health post- novel mouse models to better understand the role of platelets doctoral fellowship in Human Genetics. He was then promoted in cancer and metastasis in collaboration with Anil Sood, to assistant professor and worked with Scott Lippman, M.D., to M.D., who discovered the systemic tumor-IL6: liver- establish the Department of Clinical Cancer Prevention in the thrombopoeitin: bone marrow platelet overproduction loop Division of Cancer Prevention, and then with Dr. Lippman and that drives Trousseau’ssyndrome in cancer.

Journal

Cancer and Metastasis ReviewsSpringer Journals

Published: Aug 15, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off